Company
Headquarters: Hangzhou, China
Employees: 804
CEO: Mr. Yeqing Zhu
HK$6.34 Billion
HKD as of July 1, 2024
US$812.2 Million
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $204.45 B |
Danaher | $177.21 B |
Siemens Healthineers AG | $63.84 B |
DexCom, Inc. | $45.21 B |
Lonza Group Ltd | $39.85 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. The company is also involved in the research and development of medical diagnostic technology; provision of technical transfers and consultation, technical, and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2013 and is headquartered in Hangzhou, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
New Horizon Health Ltd has the following listings and related stock indices.
Stock: HKEX: 6606 wb_incandescent